These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35592355)

  • 41. Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study.
    Seto T; Ohashi K; Sugawara S; Nishio M; Takeda M; Aoe K; Moizumi S; Nomura S; Tajima T; Hida T
    Cancer Sci; 2021 Apr; 112(4):1556-1566. PubMed ID: 33506571
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Capmatinib for the treatment of non-small cell lung cancer.
    Vansteenkiste JF; Van De Kerkhove C; Wauters E; Van Mol P
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):659-671. PubMed ID: 31368815
    [No Abstract]   [Full Text] [Related]  

  • 43. MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review.
    Dong Y; Xu J; Sun B; Wang J; Wang Z
    Mol Diagn Ther; 2022 Mar; 26(2):203-227. PubMed ID: 35266116
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Narrative review: mesenchymal-epithelial transition inhibitors-meeting their target.
    Safi D; Abu Hejleh T; Furqan M
    Transl Lung Cancer Res; 2021 Jan; 10(1):462-474. PubMed ID: 33569327
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A narrative review of MET inhibitors in non-small cell lung cancer with
    Santarpia M; Massafra M; Gebbia V; D'Aquino A; Garipoli C; Altavilla G; Rosell R
    Transl Lung Cancer Res; 2021 Mar; 10(3):1536-1556. PubMed ID: 33889528
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
    Cortot A; Le X; Smit E; Viteri S; Kato T; Sakai H; Park K; Camidge DR; Berghoff K; Vlassak S; Paik PK
    Clin Lung Cancer; 2022 May; 23(3):195-207. PubMed ID: 35272955
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MET targeted therapy in non-small cell lung cancer patients with
    Jørgensen JT; Urbanska EM; Mollerup J
    Transl Lung Cancer Res; 2024 Apr; 13(4):940-946. PubMed ID: 38736494
    [No Abstract]   [Full Text] [Related]  

  • 48. Interstitial lung disease associated with capmatinib therapy in a patient with non-small cell lung cancer harboring a skipping mutation of MET exon 14.
    Kanemura H; Takeda M; Shimizu S; Nakagawa K
    Thorac Cancer; 2021 Feb; 12(4):549-552. PubMed ID: 33347701
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Successful tepotinib treatment of adenocarcinoma with MET exon 14 skipping and discordant results between Oncomine Dx target test and ArcherMET: A case report.
    Onodera Y; Sekine A; Hagiwara E; Yamada S; Ikeda S; Tabata E; Kitamura H; Baba T; Komatsu S; Okudela K; Ogura T
    Mol Clin Oncol; 2023 Jun; 18(6):49. PubMed ID: 37228358
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Capmatinib for non-small cell lung cancer.
    Alzofon N; Jimeno A
    Drugs Today (Barc); 2021 Jan; 57(1):17-25. PubMed ID: 33594387
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Capmatinib‑associated interstitial lung disease in a patient with lung adenocarcinoma harboring a skipping mutation of mesenchymal‑epithelial transition exon 14: A case report.
    Lee BJ; Chang CY
    Oncol Lett; 2023 Oct; 26(4):455. PubMed ID: 37720677
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MET-targeted therapies for the treatment of non-small-cell lung cancer: A systematic review and meta-analysis.
    Xu L; Wang F; Luo F
    Front Oncol; 2022; 12():1013299. PubMed ID: 36387098
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tepotinib Improves Prognosis in an Elderly Patient with Poor Performance Status and
    Tanaka A; Kashizaki F; Sugimoto S; Hattori S; Yazaki N; Obayashi S; Kitahara A; Asano K
    Tokai J Exp Clin Med; 2022 Apr; 47(1):41-43. PubMed ID: 35383870
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring
    Stargardter M; McBride A; Tosh J; Sachdev R; Yang M; Ambavane A; Mittal M; Vioix H; Liu FX
    J Med Econ; 2021; 24(1):816-827. PubMed ID: 34126842
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Meeting an un-MET need: Targeting MET in non-small cell lung cancer.
    Michaels E; Bestvina CM
    Front Oncol; 2022; 12():1004198. PubMed ID: 36338701
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report.
    Makimoto G; Shimonishi A; Ohashi K; Ninomiya K; Higo H; Kato Y; Fujii M; Kubo T; Ichihara E; Hotta K; Tabata M; Maeda Y; Kiura K
    Case Rep Oncol; 2022; 15(2):494-498. PubMed ID: 35702678
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
    Wu YL; Zhang L; Kim DW; Liu X; Lee DH; Yang JC; Ahn MJ; Vansteenkiste JF; Su WC; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan DSW
    J Clin Oncol; 2018 Nov; 36(31):3101-3109. PubMed ID: 30156984
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.
    Kim S; Kim TM; Kim DW; Kim S; Kim M; Ahn YO; Keam B; Heo DS
    Cancer Res Treat; 2019 Jul; 51(3):951-962. PubMed ID: 30309221
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Going After
    Cancer Discov; 2019 Aug; 9(8):OF9. PubMed ID: 31209157
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts.
    Zhu K; Lv Z; Xiong J; Zheng H; Zhang S; Jin H; Yu L; Li Z; Zhang J; Li C; Liang P
    Aging (Albany NY); 2021 Feb; 13(5):6890-6903. PubMed ID: 33621951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.